Treatment of Dyspareunia with Botulinum Neurotoxin Type A: Clinical Improvement and Influence of Patients' Characteristics

The treatment of chronic pelvic pain (CPP) with botulinum neurotoxin type A (BoNT/A) has increased lately, but more studies assessing its effect are needed. This study aimed to evaluate the evolution of patients after BoNT/A infiltration and identify potential responders to treatment. Twenty-four wo...

Full description

Saved in:
Bibliographic Details
Published in:International journal of environmental research and public health 2021-08, Vol.18 (16), p.8783
Main Authors: Tarazona-Motes, Marta, Albaladejo-Belmonte, Monica, Nohales-Alfonso, Francisco J, De-Arriba, Maria, Garcia-Casado, Javier, Alberola-Rubio, Jose
Format: Article
Language:English
Subjects:
Back pain
Body mass index
Botulinum toxin
Botulinum Toxins, Type A - therapeutic use
Chronic Pain
Clinical trials
Dyspareunia - drug therapy
Electromyography
Female
Humans
Low back pain
Muscles
Neurotoxins
Pain
Patients
Pelvic Pain - drug therapy
Pelvis
Quality of Life
Questionnaires
Risk analysis
Risk factors
Toxins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The treatment of chronic pelvic pain (CPP) with botulinum neurotoxin type A (BoNT/A) has increased lately, but more studies assessing its effect are needed. This study aimed to evaluate the evolution of patients after BoNT/A infiltration and identify potential responders to treatment. Twenty-four women with CPP associated with dyspareunia were treated with 90 units of BoNT/A injected into their pelvic floor muscle (PFM). Clinical status and PFM activity were monitored in a previous visit (PV) and 12 and 24 weeks after the infiltration (W12, W24) by validated clinical questionnaires and surface electromyography (sEMG). The influence of patients' characteristics on the reduction in pain at W12 and W24 was also assessed. After treatment, pain scores and the impact of symptoms on quality of life dropped significantly, sexual function improved and sEMG signal amplitude decreased on both sides of the PFM with no adverse events. Headaches and bilateral pelvic pain were risk factors for a smaller pain improvement at W24, while lower back pain was a protective factor. Apart from reporting a significant clinical improvement of patients with CPP associated with dyspareunia after BoNT/A infiltration, this study shows that clinical characteristics should be analyzed in detail to identify potential responders to treatment.
ISSN:1660-4601
1661-7827
1660-4601
DOI:10.3390/ijerph18168783